Skip to content

ERic Acute StrokE Recanalization (ERASER)

ERic Acute StrokE Recanalization (ERASER)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02534701
Acronym
ERASER
Enrollment
53
Registered
2015-08-28
Start date
2015-05-31
Completion date
2017-07-31
Last updated
2017-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

stroke, clot retrieval system, recanalization

Brief summary

To monitor the effect of the ERIC® device in combination with SOFIA™ Distal Access Catheter on artery recanalization and on clinical outcomes in stroke patients using data from clinical routine application (ERASER). To additionally evaluate the effect of the ERIC® device in combination with SOFIA™ Distal Access Catheter on the final infarct volume as determined by advanced image postprocessing methods in the subgroup of patients with acute middle cerebral artery stroke (ERASER+).

Detailed description

This is a prospective, international, single-arm, controlled, open label post-market, multicenter study to compare the safety and effectiveness of ERIC® device in combination with SOFIA™ Distal Access Catheter in acute ischemic stroke patients using clinical routine data. Patients who meet the imaging inclusion criteria for ERASER will be included in the cohort where collected and additionally analyzed data will be compared to a historical patient cohort (referred to as ERASER imaging =ERASER+). All other patients will be included in a registry (referred to as ERASER), where clinical information will be collected. The overall study duration is expected to be 18 Months. The expected duration of each subject's enrolment is approximately 90 days. Subjects will be followed with assessments at 90 days post stroke. The basic concept of ERASER+ is the use an infarct prediction algorithm that has been trained on a large dataset of historical imaging data of patients treated with IV tPA, apply it to the pre-treatment imaging and compare its predictions with the actual outcome.

Interventions

DEVICEERIC® and SOFIA™

a self-expanding clot retrieval system

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute ischemic stroke with NIH-SS score of 8-25 * CTP/ MRP \<4.5h after symptom onset completed * CTA/ MRA confirms M1-occlusion * Groin puncture estimated \<6h after stroke onset * Intended usage of ERIC® as first device in combination with SOFIA™ Distal Access -Catheter (secondary bail-out with other devices allowed)

Exclusion criteria

* MCA \>1/3 abnormal in DWI or CBV (ASPECTS ≤ 7, \>100 mL) * Pre stroke mRS ≥ 2 * Necessity of ipsilateral internal carotid artery (ICA) angioplasty * Age \<18 years

Design outcomes

Primary

MeasureTime frameDescription
VOST (volume of saved tissue) = VPIv- VMT30 hvolume of saved tissue (VOST) as difference of the brain volume with an infarct risk of \>50%, based on a prediction- algorithm trained in a historical cohort treated with IV tPA (VPIv) and the actual infarct volume

Secondary

MeasureTime frameDescription
mRS≤290 daysneurological outcomes (mRS≤2)
NIHSS score improvement ≥10 from baseline90 daysneurological outcomes (NIHSS score improvement ≥10 from baseline)

Countries

Germany, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026